CUTISS AG successfully raises CHF 25 million in Series C funding round

21-05-2024 – (Image credit: Our alumni project, denovoSkin (now known as CUTISS AG) has successfully closed its first CHF 25 million in its Series C funding round. This first closing allows CUTISS to enter Phase 3 clinical trials for its personalized skin therapy denovoSkin, which recently announced positive results in Phase 2.

Cutiss Team

The Series C round is co-led by the family office of Giammaria Giuliani, a longstanding lead investor, and a new co-lead investor, a US family represented by Shiloh Advisors AG. The company continues to welcome new investors to join its journey towards commercialization.

Daniela Marino, CEO and co-founder of CUTISS, commented: “Securing the first CHF 25 million in our Series C funding round is a pivotal achievement for CUTISS. We deeply appreciate the trust and support of our existing and new investors. This funding will enable us to continue working at speed to reach our critical development milestones and bring our life-changing treatments to patients in need. The recent positive Phase 2 clinical trial results for denovoSkin have fueled our determination to innovate further in regenerative medicine.”

This article first appeared on